Turning the complexity of a solid tumor against itself.

We are united behind a new approach to personalized immunotherapy.

Our expert leadership team draws on many decades of experience in complementary areas of biopharma development and commercialization, which they bring to bear on Imvax’s strategy to deliver a portfolio of therapies targeting solid tumors.

Personalized, whole tumor-derived immunotherapies.

OUR SCIENCE: Harnessing decades of research and multiple validated technologies, Imvax’s unique platform captures a tumor’s full antigen signature and uses it to stimulate the patient’s innate and adaptive immunity against remaining tumor cells

OUR PIPELINE: With promising clinical data in Glioblastoma and preclinical data in multiple other solid tumors, Imvax is developing a diverse pipeline of personalized, whole tumor-derived treatments

“Our highest priority and motivation are the patients, families and caregivers.”
David Andrews, M.D.

Co-Founder and Chief Medical Officer

LEARN MORE ABOUT IMVAX

If you have further questions, you are welcome to contact us at:
267-900-4110
contact@imvax.com

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614

DONATE

Our Case For Change

EBCI In The News

Patient Support Services

Patient Resource Center

VOLUNTEER WITH EBCI

GET IN TOUCH

corporate partners

upcoming events

resources

About us